Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized ketamine for acute COPD exacerbation
IRCT20200809048341N3Phase 3Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Ketamine + standard treatment with Placebo + standard treatment (2 arms). Primary endpoints: Peak expiratory flow rate, Respiratory rate and 11 more. Started Mar 2023; status: completed.
02
Drugs
ketamine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on IRCT20200809048341N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200809048341N3.